Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Filter Content:
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Symposiums
Dermatology
15
Mins
23 Mar 2021
The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists
Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…
Hematology
8
Mins
23 Mar 2021
Is CD37-Targeted Therapy a Viable Alternative in the Treatment of Diffuse Large B-cell Lymphoma? Interviews with Two Key Opinion Leaders
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and the most frequent non-Hodgkin lymphoma (NHL) in adults, accounting for 30–40%…
Dermatology
11
Mins
25 Feb 2021
Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab
The indicative scaly, erythematous plaques of plaque psoriasis arise because of abnormal interactions between immune system cells and epidermal…
Rheumatology
10
Mins
19 Feb 2021
Diagnosis, Treatment Management, and the Genetic Basis of Psoriasis, Psoriatic Arthritis, and Spondyloarthritis
Psoriatic arthritis (PsA) is an inflammatory condition of the joints and the areas where tendons and ligaments connect with bone…
Oncology
3
Mins
19 Feb 2021
Final Results from the ClarIDHy Phase III Study of Ivosidenib Versus Placebo in Patients with Previously Treated Cholangiocarcinoma and an Isocitrate Dehydrogenase 1 (IDH1) Mutation
Cholangiocarcinoma (CCA) is a rare cancer for which there are limited effective therapies.1,2 Mutations in the isocitrate dehydrogenase 1 gene (IDH1)…
Dermatology
9
Mins
18 Feb 2021
Biological and Clinical Impacts of Ultraviolet-A on the Skin: New Insights
Terrestrial solar UVR consists of UVA (320–400 nm) and UVB (280–320 nm; typically around 295–320nm because of attenuation by the ozone…
Gastroenterology
10
Mins
11 Feb 2021
TDM and T2T – Perfect Partners?
This webinar opened with an introduction to therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) by Dr Baert, as well as an explanation…
Dermatology
11
Mins
10 Feb 2021
Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis
Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…
Loading posts...
« Previous
1
…
27
28
29
30
31
…
75
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View